Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503

Molecular Cancer Therapeutics

Volumn 5, Issue 10, 2006, Pages 2484-2493

  Shiah, Her Shyong ^a,b   Gao, Wenli ^a   Baker, David C ^c   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; DCB 3503; GEMCITABINE; HYDROXYUREA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NOCODAZOLE; NSC 716802; PROTEASOME INHIBITOR; SYNAPTOTAGMIN; TYLOPHORINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL FATE; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; INDOLIZINES; NF-KAPPA B; PANCREATIC NEOPLASMS; PHENANTHRENES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; TUMOR STEM CELL ASSAY;

EID: 33750457941     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0146     Document Type: Article

References (38)

1. Li Z, Zhong J, Huang R. Isolation, total synthesis and biological activity of phenanthroindolizidine and phenanthroquinolizidine alkaloids. Synthesis 2001; 16:2365-78.
2. Gao W, Lam W, Zhong S, Kaczmarek C, Baker DC, Chang YC. Novel mode of action of tylophorine analogs as antitumor compounds. Cancer Res 2004;64:678-88.
3. You X, Pan M, Gao W, et al. Effects of a novel tylophorine analog on collagen-induced arthritis through inhibition of the innate immune response. Arthritis Rheum 2006;54:877-86.
4. lpr mice. Arthritis and Rheum 2006; 54:3277-83.
5. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
6. Gold EB, Goldin SB. Epidemiology of and risk factors for pancreatic cancer. Surg Oncol Clin N Am 1998;7:67-91.
7. Blaszkowsky L. Treatment of advanced and metastatic pancreatic cancer. Front Biosci 1998;3:E214-25.
8. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15: 2403-13.
9. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
10. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;5:412-7.
11. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2:897-909.
12. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor κB in pancreatic cancer metastasis. Clin Cancer Res 2003;9:346-54.
13. Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003;101: 3126-35.
14. Mayo MW, Wang CY, Cogswell PC, et al. Requirement of NF-ΚB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997;278:1812-5.
15. Li L, Aggarwal BB, Shishodia S, Abbruzzese J, Kurzrock R. Nuclear factor-κB and IκB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 2004;101:2351-62.
16. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol 2002;10:153-69.
17. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42.
18. Chen S, Fribley A, Wang CY. Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-κB inhibitor. J Dent Res 2002;81:98-102.
19. Wang CY, Mayo MW, Baldwin AS, Jr. TNF-α and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996;274: 84-7.
20. Chen LF, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 2004;5:392-401.
21. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115: 2625-32.
22. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003;8:508-13.
23. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004;10:617-24.
24. Dewan MZ, Terashima K, Taruishi M, et al. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/ γc(null) mice: suppression by an inhibitor against NF-κB. J Virol 2003;77: 5286-94.
25. Chung DC, Brown SB, Graeme-Cook F, et al. Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. J Clin Endocrinol Metab 2000;85:4373-8.
26. Gansauge S, Gansauge F, Ramadani M, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997;57:1634-7.
27. Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger HG, Korc M. Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology 1998;55:363-9.
28. Kornmann M, Arbor N, Korc M. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998; 101:344-52.
29. Biliran H, Jr., Wang Y, Banerjee S, et al. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 2005; 11:6075-86.
30. Kornmann M, Danenberg KD, Arbor N, Beger HG, Danenberg PV, Korc M. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 1999; 59:3505-11.
31. Finlay GJ, Baguley BC, Wilson WR. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 1984;139:272-7.
32. Ding XZ, Kuszynski CA, El-Metwally TH, Adrian TE. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun 1999;266:392-9.
33. Arias AE, Bendayan M. Differentiation of pancreatic acinar cells into duct-like cells in vitro. Lab Invest 1993;69:518-30.
34. Saccani S, Marazzi I, Beg AA, Natoli G. Degradation of promoter-bound p65/ReIA is essential for the prompt termination of the nuclear factor-κB response. J Exp Med 2004;200:107-13.
35. Birbach A, Gold P, Binder BR, Hofer E, de Martin R, Schmid JA. Signaling molecules of the NF-κB pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem 2002;277:10842-51.
36. Jiang X, Takahashi N, Ando K, Otsuka T, Tetsuka T, Okamoto T. NF-κB p65 transactivation domain is involved in the NF-κB-inducing kinase pathway. Biochem Biophys Res Commun 2003; 301:583-90.
37. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression. Nature 2003;423:655-9.
38. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression. Nature 2003;423:659-63.